InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,181.20
(
-0.43%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.85
(
0.00%
)
Bitcoin
60,645.70
(
0.55%
)
Post# of 252426
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Summer2762

Send PM Follow Ignore
Followers 7
Posts 193
Boards Moderated 0
Alias Born 10/26/2011

Summer2762

Re: Summer2762 post# 142833

Sunday, 06/03/2012 1:16:59 AM

Sunday, June 03, 2012 1:16:59 AM

Post# of 252426
COU-AA-302 Data Summary & Perspectives on ZYTIGA® (abiraterone acetate) in chemotherapy-naive patients: Recorded Webcast Update for Analysts and Investors

http://www.investor.jnj.com/common/download/download.cfm?companyid=JNJ&fileid=573498&filekey=d69d9c36-61a7-4fb7-927a-fb7c802f3b31&filename=FINAL%20ZYTIGA%20Webcast%20Update%205-31-2012.pdf

Not that the behavior of the patients in the trial will truly reflect the behavior of the patients in the real world, I was nevertheless surprised to see docexatel usage after abi (Zytiga) to be above 50% even at the interim. (Yet another important input if you are an OGXI investor)


Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up